Overexpression of ABC transporters leads to MDR (Multiple Drug Resistance). MDR is considered to be the major contributor to failure of chemotherapy in metastatic cancers. ABC transporters have protective role in normal cells by extruding xenobiotics of cytotoxic compounds from the cell. The development of selective inhibitors of P-gp, MRP1, MRP2, and BCRP has been a major goal of many research groups in the last few years. Previous studies have shown that 1,4-dihydropyridines could inhibit these transporters. In this study, some new 1,4-dihydropyridine and pyrimidine have been developed and their inhibitory effect on the resistant cancer cell lines was examined. In order to elucidate the binding mode of these compounds, a molecular docking and molecular dynamic simulation was performed for the protein-ligand complex. Dihydropyridines were more potent than dihydropyrimidines. However, one of the dihydropyrimidine derivatives selectively inhibited BCRP. The binding mode of these compounds showed that methoxy groups and heterocyclic rings could create hydrogen bonds with polar residues at the active sites. These regions were more stable during MD simulation.
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Introduction
Cancer is one of the highest causes of deaths today. Chemotherapy has been known and used to give patients a fighting chance. Multiple Drug Resistance (MDR) is responsible for the 90% failure of chemotherapy in metastatic cancer (Gottesman and Ling, 2006) . The most important agent of the MDR is overexpression of ATP binding cassette (ABC) transporters in the resistant cancer cells (Choi, 2005; Huang and Sadée, 2006) . ABC transporters are transmembrane proteins that efflux structurally varied anticancer drugs which produce resistance to diverse anticancer drugs (Lage, 2008; Sharom, 2008) . Based on the sequence similarity 49 known ABC transporters are classified into different seven subfamilies, out of which ABCB1(P-gp), ABCC1(MRP1) and ABCG2(BCRP) are the most relevant ABC transporters in the MDR (Dean et al., 2001; Dean and Annilo, 2005; Vasiliou et al., 2009 ). The ABC transporter plays a protective role by extruding xenobiotic from normal cells. In addition they transport biologically important substrate including amino acids, sugars, etc. (Gottesman and Ambudkar, 2001 ). P-gp (ABCB1) is a 170 kDa protein with 1283 amino acids which transport substrates including anthracyclines vinca alkaloids, taxanes, and epipodophyllotoxins (Gottesman et al., 2002) . BCRP (ABCG2) is a 72 kDa half transporter which transports mitoxantrone, camptothecins, anthracyclines, methotrexate, and flavopiridol (Mao, 2005) .
The only known way to overcome MDR is the development of inhibitors of these efflux pump activities (Avendaño and Menéndez, 2004) . The most important obstacle in the application of such inhibitors is the massive side effects of these inhibitors in causing inhibition of other natural body efflux pumps which detoxifies the normal cells (Leschziner et al., 2007) . This toxicity increases during chemotherapy and coadministration of anticancer drugs. A way around this is the development of a selective inhibitor of P-gp, MRP1, MRP2, and BCRP that reduces the side effects of such inhibitors. In this study, P-gp and BCRP inhibition induced by some new 1,4-dihydropyridine (A1, 2) and pyrimidine (B1, 2) were investigated. In order to elucidate the binding mode of these compounds, a molecular docking and molecular dynamic simulation for the protein-ligand complex was performed.
Materials and methods

Chemical
Compounds including verapamil, fumitremorgin C, and mitoxantrone were purchased from Sigma Aldrich. Test compounds were synthesised by the method of Mohammadpour (2012) and Rashidifar et al. (2014) . These compounds were re-synthesised, using the same approach used in the earlier study (Figure 1 ). 
Cell culture
Culture medium, RPMI1640, fetal bovine serum (FBS) and penicillin streptomycin were purchased from Biosera. MCF7/parental, MCF7/ADR, and MCF7/MX were obtained from Biotechnology Laboratory stock (Biotechnology Research Center, Mashhad, Iran) . Cells were grown in RPMI1640 with 10% FBS, penicillin 100 units/ml, streptomycin 100 mg/ml at 37°C and humid atmosphere containing 5% CO 2 . MCF7/ADR (doxorubicin resistant and P-gp overexpressing cells) were cultured in the presence of 300 ng/ml doxorubicin for two weeks and one week without doxorubicin before test. This procedure was performed exactly for MCF7/MX (mitoxantrone resistance cell, BCRP or ABCG2 overexpressing cell) with 300 ng/ml mitoxantrone on the resistant cells.
MTT cytotoxicity assay
To determine the cytotoxic effect of test compounds MTT cytotoxicity assay was performed. In summary, a mixture containing 5000 number of MCF7/P cells were seeded in the 96 well plates and cultured overnight. Subsequently, the medium was replaced with one containing different concentrations of test compounds (5-100 µM). After incubation for 24 h the cells were treated with final concentration of 0.5 mg/ml MTT solution for 3 h. Then the medium was removed and 100 ul DMSO (dimethyl sulfoxide) added to each cell, in order to dissolve formazan crystal. The absorbance was measured at 545 nm (630 nm as reference) using Synergy H4 micro-plate reader.
P-gp and BCRP inhibition assay
In order to determine the inhibition of P-gp and BCRP induced by test compounds MCF7/ADR (p-gp overexpressing cells) and MCF7/MX (BCRP over expressing cells) were seeded 2.5 × 10 4 cell/well in a 12 well plate. After 48 h cells grew confluently and the medium was removed and replaced with one containing different concentrations of test compounds. After incubation for 5 min each well was treated with 5 µM fluorescent substrate (Rhodamine 123 for P-gp, mitoxantrone for BCRP). After incubation for 45 min at 37°C, cells were washed two times with ice-cold PBS and trypsinised. After centrifugation, the cells were resuspended in 0.5 ml ice-cold PBS and stored on ice until measurement. Fluorescence of 10,000 events was measured using BD FACSCalibur Flow 168 Cytometry System (BD Biosciences, San Jose, USA).
Molecular modelling
Structure preparation
3D structures of the chemicals were prepared using Gaussian 09 software (Frisch et al., 2009 ). AM1-semiempirical calculation after molecular mechanic pre-optimisation was performed. The X-ray structure of mouse P-glycoprotein inward facing conformation (PDB ID 4M2S) (Li et al., 2014) and ATP-bound (PDB ID 1MV5) (Yuan et al., 2003) were downloaded from RCSB protein data bank. The sequence of ABCB1 was obtained from UniProt (ID P08183) (Consortium, 2008) . Modeller 9.14 (Webb and Sali, 2014) was used to make homology modelling of human ABCB1 from sequence and structures. Quality of the model created was assessed by Ramachandran plot (Figure 2 ). The homology modelling of BCRP based on the mouse apoprotein was generated previously by Rosenberg and Bikadi (Hazai and Bikádi, 2008; Ni et al., 2010; Rosenberg et al., 2010) . These two structures were refined and energy minimised with MOE 2008 (Chemical Computing Group, 2015 .
Docking
The residues known to interact with verapamil, QZ-59-RR, QZ55-SS, and ATP-site were selected as active site in homology model of the P-gp (Aller et al., 2009) . It is shown that ARG482 has an important role in the human BCRP Rosenberg et al., 2010) . This residue was selected as the centre of docking. The docking was performed with MOE 2008 and London DG was used as scoring function. Top scoring conformations of docked ligands were selected for further analysis. 
MD simulation
The complex of the best conformation of docked ligands and protein was used for molecular dynamic simulation using Gromacs 4.5.5 (Pronk et al., 2013) . Gromos 53a6 (for BCRP) and CHARM27 (for P-gp) were selected as force field (Gadhe et al., 2013; Liu et al., 2013) . PRODRG (SchuÈttelkopf and Van Aalten, 2004) (for BCRP) and Swiss Pharm (Zoete et al., 2011 ) (for P-gp) servers were used to create topology and coordinates of the ligands. The partial charges of the ligands were edited using output of Gaussian from AM1-semiempirical calculation (Lemkul et al., 2010) . The complex was adjusted in the cubic box filled with single point charge water (SPC) and minimum 0.5 nm from the edge of box. After addition of proper counter ions for neutralisation of system 5000 steepest descent minimisation (force constant of 1000 kj/mol) was performed to remove excessive strains. After minimisation, the complex was stabilised to a temperature (310K) and pressure (1bar) for 100 ps. Restrain was applied for proteinligand. The neighbour updated every ten steps. The time step was 0.002 ps. we used LINCE algorithm (Hess et al., 1997) . The electrostatic interactions were calculated with particle mesh Evalte method (PME, cut of 1.2) and Lennard-Jones method was used for calculation of van der Waals interactions (cut of 1.4). V-rescale coupling (Bussi et al., 2007) was used to keep temperature and Parrinello-Rahman (Parrinello and Rahman, 1981) to keep pressure constant during simulation. Finally, 1000 ps simulation for the complex of protein and ligand was performed.
Results and discussion
Cytotoxicity assay
The cytotoxic effect of test compounds on MCF7/P cells was determined using MTT assay. The result of test showed that dihydropyrimidines (B1, B2) had IC 50 values more than 100 µM, but dihydropyridines (A1, A2) were more toxic (IC 50 79 ± 5 µM and 72 ± 10 µM, respectively). Indeed, there were great restrictions in the use of these compounds in high concentrations.
P-gp and BCRP inhibition profile
P-gp inhibition was assigned as fluorescent ratio of fluorescent substrate Rhodamine 123 in MCF7/ADR cells after treatment with inhibitor to un-treated control cells (Table 1) . A1 and A2 showed the inhibition of P-gp at 20 µM but B1 and B2 were inactive at the same concentrations. Verapamil (positive control) shows strong inhibition of P-gp. There was no significant change in inhibition activity with substitution of 2-chlorobenzyl (in A1) with 4-fluorobenzyl (A2). Previous studies have shown that the common feature of the transmembrane modulator is lipophilicity (Coburger et al., 2010) . A1 and A2 are more lipophilic than B1, B2 (Table 2) . Drug binding site of P-gp consists of aromatic hydrophobic, and polar aromatic residues (Aller et al., 2009) . This means that a lipophilic compound that carries sites to make hydrogen bonds with these residues can be a good pump inhibitor. Verapamil is less lipophilic than A1 and A2 but is a strong inhibitor of P-gp. Verapamil carries four methoxy groups and a nitrile group. Perhaps these groups enabled verapamil to create hydrogen bond with active site of P-gp.
BCRP inhibition was determined by accumulation of fluorescent substrate mitoxantrone in MCF7/MX cells, after treatment with inhibitor in comparison to un-treated control cells. BCRP inhibition profile was similar to P-gp, but B2 was a more potent inhibitor of BCRP. It seemed that with increasing concentration of B2, better specific inhibition of BCRP was observed. Additionally, this compound was non-toxic. Better activity of this compound compared to B1 is elucidated in the docking studies. This compound showed some interaction with Arg482 which is important for the efflux activity of the BCRP. No significant change in inhibition activity with increasing concentration of A1 and A2 (unlike P-gp) was seen. Perhaps at concentration of 50 µM, A1 and A2 inhibited P-gp stronger than BCRP, but at this concentration A1 and A2 were cytotoxic. Table 1 Concentration and inhibition of P-gp and BCRP induced by test compounds. Calculated inhibition values are the each measured fluorescence intensity in the inhibitor-treated cells related to inhibitor-untreated control 
Docking studies
To investigate the binding mode of these compounds with P-gp, computational docking was performed. A correlation between docking scores and inhibition activity of these compounds was seen (Figure 3 ). This correlation was highest with London DG scoring function in MOE. A1 carries one Pi interaction with Phe343 and two hydrogen bonds with Glu310 and Glu880. B2 showed hydrogen bond with Tyr310. Docked structures of verapamil showed several hydrogen bonds between polar residues in active site and methoxy groups. It can be seen that the active site of P-gp consisted of aromatic and grassy residues (Phe, leu, Val, Ala) and polar ones (Glu, Tyr, Gln). It can be concluded from docking studies that methoxy and nitrile groups of verapamil enabled this compound to create hydrogen bonds with polar residue in the active site of P-gp. A correlation between docking scores and inhibition of BCRP can be seen with the London DG scoring function. A1 shows two arene-cation interactions with Arg 482 and Pi interactions with Phe385 and Cys518. A2 carries a Pi interaction with Arg482 and Cys518. B2 shows two Pi interactions with Arg482 and Phe385. These interactions arise from the imidazole ring. FMC carries Pi and hydrogen bond with Arg482 and Cys518. Similar P-gp active site of BCRP consists of polar and lipophilic residues. A relationship can be seen between the ability of this compound in inhibition of BCRP and making hydrogen bonds with polar residues in the active site, especially Arg482 (Figure 4 ).
MD simulation
P-gp
For better elucidation of the binding mode of these compounds to the active site, 1000 ps MD simulation of the protein-ligand complex in an aqueous box was performed. A1 became consistent after 200 ps. The last frame coordinate shows that A1 moved towards Tyr118 ad Tyr950. Two heterocyclic rings (pyridine and imidazole) and carboxamide groups showed the lowest fluctuation during simulation. Maybe these sites had a powerful interaction with the active site of P-gp. Disorientation of A2 is greater than A1 but after 500 ps became more consistent. A2 became consistent on the Glu946 and Ser344 and Tyr950. Similar to the A1 fluctuation of heterocyclic rings and carboxamide group was lowest during the simulation. After 600 ps B1 showed a great displacement and became consistent on Tyr950, Tyr118 and Met69. After 200 ps, B2 was consistent on the Glu725, Glu990 and Met986. In these compounds, the imidazole and pyrimidine ring is more consistent. The last frame position of verapamil was around Glu948, Try935 and Phe983. Methoxy and nitrile groups were the positions with the lowest fluctuation (Figures 5-6 ). 
BCRP
At the beginning of the simulation, A1 replaced 2Aº and became consistent on Arg482 with Pi interaction. The behaviour of A2 was similar to A1 and was consistent on the Arg482. The FMC became consistent after 200 ps on the Arg482 with Pi interaction. B1 became consistent after 200 ps and shows movement towards Arg383 and Ser384. B2 moved 1Aº and became consistent on leu478 with hydrogen bond. The fluctuation pattern of these compounds on the active site of BCRP is similar to P-gp but the methylthio groups in all the compounds showed a higher fluctuation (Figures 5-6 ). 
interaction mode of verapamil with P-gp, and (4) interaction mode of A2 with P-gp (all of these interaction modes are after MD simulation) (see online version for colours)
Conclusion
It can be concluded from this study that a good inhibitor of the ABC transporters is a lipophilic compound which has groups enabling to make hydrogen bonds with polar residues on the pump. In order to design a potent inhibitor of the pump, phenyl ring with methoxy groups, imidazole, pyridine and other heterocyclic rings, must be added to dihydropyridines. B2 was able to selectively inhibit the BCRP (with low effect on the P-gp). B2 can be used as a lead compound to create better selective inhibitors of the BCRP.
